Nutra Pharma Corp.'s latest marketcap:
As of 07/05/2025, Nutra Pharma Corp.'s market capitalization has reached $709,974. According to our data, Nutra Pharma Corp. is the 48264th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 709,974 |
| Revenue (ttm) | 247,767 |
| Net Income (ttm) | 7.11 M |
| Shares Out | 7.1 B |
| EPS (ttm) | 0 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | n/a |
Nutra Pharma Corp.'s yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $709,974 | 0% | 48264 |
| 12/31/2024 | $709,974 | 9949.17% | 47648 |
| 12/20/2023 | $7,065 | -99.07% | 45975 |
| 12/30/2022 | $759,685 | -94.82% | 44251 |
| 12/31/2021 | $14.65 M | 106.12% | 42248 |
| 12/31/2020 | $7.11 M | 189.33% | 39062 |
| 12/31/2019 | $2.46 M | 104.22% | 36403 |
| 12/31/2018 | $1.2 M | -7.77% | 35032 |
| 12/29/2017 | $1.3 M | -37.71% | 33531 |
| 12/30/2016 | $2.09 M | -50.61% | 31529 |
Company Profile
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company focused on acquiring, licensing, and commercializing pharmaceutical products and technologies. The company specializes in homeopathic and ethical drugs designed to manage pain, neurological disorders, cancer, and autoimmune and infectious diseases, primarily serving the U.S. market.
Key Products
- Nyloxin & Nyloxin Extra Strength: Oral sprays and topical gels for pain relief, including lower back pain, migraines, arthritis, and neuropathic pain.
- Pet Pain-Away: A non-narcotic, non-addictive homeopathic pain reliever for companion animals.
- Luxury Feet: An OTC anti-inflammatory product for foot pain caused by high heels and stilettos.
- Nyloxin Military Strength: A specialized pain relief solution for U.S. Military and Veteran's Administration use.
- Equine Pain-Away: A topical pain reliever for horses.
Research & Development
Nutra Pharma is actively developing innovative treatments, including:
- RPI-78M: Targeting neurological and autoimmune diseases such as multiple sclerosis, ALS, and rheumatoid arthritis.
- RPI-MN: Focused on viral diseases like HIV/AIDS and herpes, with broader antiviral applications.
- RPI-78 & RPI-70: Designed for pain and arthritis management.
Founded: 2000 | Headquarters: Plantation, Florida
Frequently Asked Questions
-
What is Nutra Pharma Corp.'s (OTC-NPHC) current market cap?As of 07/05/2025, Nutra Pharma Corp. (including the parent company, if applicable) has an estimated market capitalization of $709,974 USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Nutra Pharma Corp. (OTC-NPHC) rank globally by market cap?Nutra Pharma Corp. global market capitalization ranking is approximately 48264 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.